linjc16/ctgov huggingface dataset:
Musculoskeletal Disorders of Workers in a Production and Distribution Company in Argentina

Study Overview
=================
Brief Summary
-----------------
Describe musculoskeletal disorders of workers in a company in Argentina regarding working areas and demographic carachteristics of the workers.

Detailed Description
-----------------
We are analyzing the first consultation registration of every worker that had been attended by the physiotherapist in a clinic that is located inside the company. These records consist on demographic data and also injury related information.

Official Title
-----------------
Musculoskeletal Disorders of Workers in a Production and Distribution Company in Argentina: a Retrospective Study

Conditions
-----------------
Describe Musculoskeletal Disorders of Workers

Intervention / Treatment
-----------------
* Other: Epidemiologic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: workers in a production and distribution company in Argentina that walks into the clinic inside the company Exclusion Criteria: lack of registered information
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Epidemiologic|Epidemiologic study. Observational, transverse study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Musculoskeletal disorders | Rate of participants with musculoskeletal disorders for each demographic characteristic. The measurment tool will be a face-to-face questionnaire. | 21 months |
Incidence and Associated Factors of Persistent Postoperative Incision Scar Pain Following C/s in Mulago Hospital

Study Overview
=================
Brief Summary
-----------------
prospective cohort study of women who underwent caesarean section in mulago hospital. followed up for 2 months and assessed for development of persistent post operative pain at the incision site and its effect on quality of life. incidence of persistent postoperative pain and associated factors determined.

Detailed Description
-----------------
prospective cohort study of 277 women who underwent caesarean section in mulago hospital. demographic, medical history, intraoperative, postoperative details, and perioperative levels of pain collected. followed up by telephone interviews for 2 months and assessed for development of persistent post operative pain at the incision site and its effect on quality of life. incidence of persistent postoperative pain and associated factors determined.

Official Title
-----------------
Incidence and Associated Factors of Persistent Postoperative Incision Scar Pain Following C/s in Mulago Hospital

Conditions
-----------------
Chronic Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - ASA I, II, and III. patient who has given informed consent. Exclusion Criteria: patients who have no telephone contact
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| persistent postoperative pain at caesarean section incision scar site. | participant report pain at site of caesarean section incision site scar at 2 months after caesarean section. | 2 months. |
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Study Overview
=================
Brief Summary
-----------------
This is an observational study that will monitor clinical outcomes of patients who have received a NiCord®/CordIn™ (omidubicel) transplant as part of a GC clinical interventional study and meet the eligibility criteria for this Long Term Follow Up study.

Official Title
-----------------
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells

Conditions
-----------------
Patients Transplanted With NiCord/CordIn (Omidubicel)

Intervention / Treatment
-----------------
* Genetic: NiCord®/CordIn™ (omidubicel)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Anyone who has received a NiCord®/CordIn™ (omidubicel) transplant, completed study specific follow up, and has signed the consent for this study. Exclusion Criteria None

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NiCord®/CordIn™ (omidubicel) transplanted<br>Anyone who signed the consent for this study received a NiCord®/CordIn™ (omidubicel) infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment. | Genetic: NiCord®/CordIn™ (omidubicel)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| long term sustained chimerism of NiCord®/CordIn™ (omidubicel) transplantation |  | 5 years |
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety and tolerability of subcutaneous Fuzeon in patients with advanced HIV-1 infection unable to construct an appropriate treatment regimen from currently available antiretroviral agents. The anticipated time on study treatment is 3-12 months, and the target sample size is 9 individuals.

Official Title
-----------------
Open Label, Nonrandomized Clinical Trial of Safety and Tolerability of Enfuviritide (Fuzeon®, HIV Fusion Inhibitor) in Patients With Advanced HIV1 Infection

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: enfuvirtide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult or adolescent patients greater than (>)16 years of age HIV-1 infection CD4 count less than (<)350/cubic millimeters (mm^3) HIV RNA viral load >10,000 copies per milliliter (copies/mL) while on highly active antiretroviral therapy (HAART) Documented resistance, treatment-limiting toxicity, and/or >=6 months' prior experience with each of 3 currently available classes of antiretroviral drugs. Exclusion Criteria: Women who are pregnant or breastfeeding; Patients unable to self-inject; Active, untreated opportunistic infection.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Enfuvirtide<br>Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections | Drug: enfuvirtide<br>* Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.<br>* Other names: Fuzeon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of participants who discontinue enfuvirtide due to adverse events\n |  | Up to 102 weeks | 
| Percentage ofparticipants who discontinue from tratment since they no longer wish to continue with the injections |  | Up to 102 weeks | 
| Percentage of participants with Serious Adverse Events (SAEs) and Serious AIDS-Defining events |  | Up to 102 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage os participants reporting serious adverse events on the first day of study dosing and up to 28 days after discontinuiation of the study drug |  | Up to 28 days after discontinuation of enfuvirtide | 
| Percentage of participants with Injection Site Reactions (ISR) and who discontinued enfuvirtide due to ISR |  | Up to 102 weeks |
National Survey on the Lockdown of Children With Disabilities

Study Overview
=================
Brief Summary
-----------------
During the COVID-19 pandemic, lockdown measures were established in France affecting the life course of children with disabilities. This study aimed at identifying the experiences, main difficulties and needs of these children and their parents during the lockdown period.

Official Title
-----------------
Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic: Messages From Families Answering the ECHO French National Survey

Conditions
-----------------
Identify Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -children (age 0-18 years) with motor disabilities (with and without associated impairement), living in France. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Experience during lockdown | Identify the lived experience, the needs, and difficulties of children with motor disabilities and their parents during the COVID-2019 lockdown | From the 6th of April 2020 until the 11th of May 2020 | 
| Health risk during lockdown | Identify the risks on health of children with motor disabilities due to the COVID-2019 lockdown | From the 6th of April 2020 until the 11th of May 2020 | 
| Impact on medical and rehabilitation follow up | Identify the impact on the medical and rehabilitation follow up of children with disabilities during COVID-19 lockdown | From the 6th of April 2020 until the 11th of May 2020 | 
| Impact on daily living | Identify the impact on the daily living of children with motor disabilities and their families during the COVID-19 lockdown | From the 6th of April 2020 until the 11th of May 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Experience during lockdown | Identify the lived experience, the needs, and difficulties of children without motor disabilities and their parents during the COVID-2019 lockdown | From the 24th of April 2020 until the 11th of May 2020 |
EEG Monitoring in Children With Moyamoya Disease

Study Overview
=================
Brief Summary
-----------------
EEG in moyamoya disease in children preoperatively

Detailed Description
-----------------
EEG monitoring in children with moyamoy disease preoperatively for 10 minutes

Official Title
-----------------
EEG Finding in Moyamoya Disease in Children

Conditions
-----------------
EEG With Periodic Abnormalities

Intervention / Treatment
-----------------
* Device: EEG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moyamoya disease Exclusion Criteria: refusal

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: EEG|EEG monitoring|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EEG | EEG finding | preoperative |
Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy

Study Overview
=================
Brief Summary
-----------------
In this randomized controlled study, consecutive outpatients scheduled for elective colonoscopy were randomized into two groups. Group A patients (n = 150) used 2 L PEG before colonoscopy. Patients in group B (n = 150) were additionally advised to chew sugarless gum plus 2 L PEG, The overall quality of colonoscopy cleaning was evaluated using the Boston Bowel Preparation Scale by endoscopists who was blinded to the intervention. Difficulty of procedure, patients' tolerance, and adverse events were also evaluated.

Official Title
-----------------
Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study

Conditions
-----------------
Bowel Preparation Scale, Adenoma Detection Rate

Intervention / Treatment
-----------------
* Dietary Supplement: gum+PEG
* Drug: polyethylene glycol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adults (18-65) who were referred for outpatient colonoscopy. Exclusion Criteria: under 18 years or More than 65 years previous abdominal surgery major psychiatric disorders pregnancy presence of any contraindications for colonoscopy(eg, severe heart failure) recent inadequate colonoscopy history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: gum+PEG<br>used 2L PEG+sugarless gum | Dietary Supplement: gum+PEG<br>* chew sugarless gum<br>|
| Placebo Comparator: PEG<br>only used 2L PEG | Drug: polyethylene glycol<br>* 2L PEG<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Boston Bowel Preparation Scale |  | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patient tolerability |  | 2 days | 
| number of patient willingness to repeat preparation |  | 2 days | 
| Adenoma Detection Rate |  | 2 days |
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

Study Overview
=================
Brief Summary
-----------------
This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.).

Official Title
-----------------
Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects With Heart Failure

Conditions
-----------------
Heart Failure, Congestive

Intervention / Treatment
-----------------
* Drug: tolvaptan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Class III or IV heart failure for at least 3 months Left ventricular ejection fraction less than or equal to 40% Currently being treated for heart failure with standard therapies for at least one month Exclusion Criteria: Women who are pregnant or breastfeeding Inability to take oral medications Uncontrolled hypertension, bradyarrhythmias or tachyarrhythmias Hypertrophic obstructive cardiomyopathy Severe obstructive pulmonary disease Significant renal impairment Significant uncorrected valvular or congenital heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: tolvaptan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in heart pressures (PCWP) at 3 to 8 hours post-dose |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in heart function measurements (CI, SVR, PVR, RAP) at 3 to 8 hours post-dose |  |  | 
| Change in urine output and free water clearance |  |  | 
| Change from baseline in urine osmolality |  |  | 
| Cmax, tmax, and AUC 12h of tolvaptan in plasma |  |  | 
| Adverse events, vital signs and clinical labs |  |  |
The Comparative Study Between Bowel Preparation Method

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy, acceptability and preparation-induced mucosal inflammation of PEG + ascorbic acid vs. PEG for colonoscopy.

Detailed Description
-----------------
This was a prospective randomized single-blinded clinical trial of ambulatory patients to assess the efficacy of bowel preparation and preparation-induced mucosal inflammation. Endoscopists who were blinded to the preparation taken, assessed both bowel cleansing by using the Ottawa bowel preparation assessment tool and preparation-induced mucosal inflammation. Acceptability was assessed by questionnaire.

Official Title
-----------------
The Comparative Study Between Bowel Preparation Method: 4L-split Dose of PEG Solution, Low-volume PEG Plus Ascorbic Acid Focusing on the Bowel Cleansing Efficacy, Patients' Affinity to Preparation Solution and Mucosal Injury

Conditions
-----------------
Colonoscopy

Intervention / Treatment
-----------------
* Drug: Colonoscopy after bowel cleansing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who want colonoscopy purposing screening among adults between the age of 20 65 Exclusion Criteria: Under the age of 20, older than 65, pregnant or lactating women, intestinal obstruction, structural intestinal disease, hypothyroidism, gastrointestinal motility, renal failure, congestive heart failure, liver failure, electrolyte abnormalities, who refused research informed consent, inflammatory bowel disease, the obvious symptoms of the disease in patients with lower gastrointestinal (bloody stools, diarrhea, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 4L-split Dose of PEG Solution<br>4L-split Dose of PEG Solution for bowel preparation | Drug: Colonoscopy after bowel cleansing<br> <br> |
| Active Comparator: Low-volume PEG Plus Ascorbic Acid<br>Low-volume PEG Plus Ascorbic Acid for bowel preparation | Drug: Colonoscopy after bowel cleansing<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of colon cleansing between the two solutions using Ottawa scale |  | 3month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BOWEL PREPARATION, PEG, Low-volume PEG Plus Ascorbic Acid
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Study Overview
=================
Brief Summary
-----------------
Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Official Title
-----------------
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Conditions
-----------------
Persistent Corneal Epithelial Defect

Intervention / Treatment
-----------------
* Drug: DE-105 ophthalmic solution
* Drug: DE-105 ophthalmic solution
* Drug: Placebo ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Has corneal epithelial defect and decreased corneal sensitivity. Has undergone continuous treatment for corneal epithelial defect for 1 week or longer. Exclusion Criteria: Presence of disease such as active ocular infection, or abnormal lid closure. History or presence of chemical burn, Stevens - Johnson Syndrome, etc. History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High concentration<br>DE-105 high concentration | Drug: DE-105 ophthalmic solution<br>* Topical ocular application<br>|
| Experimental: Low concentration<br>DE-105 low concentration | Drug: DE-105 ophthalmic solution<br>* Topical ocular application<br>|
| Placebo Comparator: Placebo<br>DE-105 placebo | Drug: Placebo ophthalmic solution<br>* Topical ocular application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Restoration of corneal epithelial defect |  | Every week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity,etc. |  | Exit visit,etc. |